OHE: Events http://www.ohe.org/object/display.cfm?serv=1 OHE - Office of Health Economics Thu, 23 May 2013 16:33:14 GMT Annual Lecture: Contracting for Qualtiy in the NHS http://www.ohe.org/object/display.cfm?serv=1&id=20#20 20 Mon, 15 Jul 2013 23:00:00 GMT Prof Alan Maynard will give OHE's 20th Annual Lecture, entitled 'Contracting for Quality in the NHS: Putting the Francis Report in Perspective'. Join us on 16 July in London. Biosimilar Competition: Lessons from Europe and Prospects for the US http://www.ohe.org/object/display.cfm?serv=1&id=19#19 19 Thu, 23 May 2013 23:00:00 GMT Based on his recent research, Prof Henry Grabowski of Duke University will discuss the factors most likely to determine market penetration by biosimilars. The Influence of Cost-Effectiveness and Other Factors on NICE Decisions http://www.ohe.org/object/display.cfm?serv=1&id=18#18 18 Mon, 22 Apr 2013 23:00:00 GMT Valuing Health at the End of Life http://www.ohe.org/object/display.cfm?serv=1&id=17#17 17 Tue, 26 Mar 2013 00:00:00 GMT Competitiveness in Follow-On R&D: Race or Imitation? http://www.ohe.org/object/display.cfm?serv=1&id=16#16 16 Tue, 27 Nov 2012 00:00:00 GMT Intellectual Property Rights and Innovation: Evidence from the Human Genome http://www.ohe.org/object/display.cfm?serv=1&id=15#15 15 Tue, 23 Oct 2012 23:00:00 GMT The Challenges and Economics of Drug Development in 2022 http://www.ohe.org/object/display.cfm?serv=1&id=12#12 12 Sun, 07 Oct 2012 23:00:00 GMT Moving in the Wrong Direction: Lessons from Tracking Successful R&D and Financing Dynamics in UK Therapeutics (Lunchtime Seminar) http://www.ohe.org/object/display.cfm?serv=1&id=13#13 13 Tue, 03 Jul 2012 23:00:00 GMT Dr Michael Hopkins of the University of Sussex will discuss his research tracking the SMEs that shows which financing strategies are most likely to generate successful projects. (Limited seating) Annual Lecture: What Constitutes Credible Evidence of Effectiveness? http://www.ohe.org/object/display.cfm?serv=1&id=10#10 10 Sun, 17 Jun 2012 23:00:00 GMT OHE's 50th anniversary annual lecture addresses an issue that is as important today as it was in 1962: what evidence is necessary to demonstrate effectiveness. Real Option Value and Path Dependence in Oncology Innovation (Lunchtime Seminar) http://www.ohe.org/object/display.cfm?serv=1&id=11#11 11 Wed, 16 May 2012 23:00:00 GMT Dr Joseph Cook, Pfizer Inc. Using Happiness to Value Health (Lunchtime Seminar) http://www.ohe.org/object/display.cfm?serv=1&id=9#9 9 Wed, 14 Mar 2012 00:00:00 GMT Prof Paul Dolan, London School of Economics and Political Science A Productivity Crisis in Pharmaceutical R&D? (Lunchtime Seminar) http://www.ohe.org/object/display.cfm?serv=1&id=8#8 8 Thu, 08 Dec 2011 00:00:00 GMT Prof Massimo Riccaboni, University of Trento (Limited seating) Potential Use of MCDA: Drawing on the EMA Project Experience (Lunchtime Seminar) http://www.ohe.org/object/display.cfm?serv=1&id=7#7 7 Wed, 07 Dec 2011 00:00:00 GMT Prof Larry Phillips, London Shool of Economics and Political Science (Limited Seating) Annual Lecture: Cost per QALY in the U.S. and Britain http://www.ohe.org/object/display.cfm?serv=1&id=2#2 2 Tue, 15 Nov 2011 00:00:00 GMT Cost per QALY in the U.S. and Britain: Damned if You Do and Damned if You Don't? Prof. Milton Weinstein, Harvard University Masterclass in Innovative Pricing Schemes http://www.ohe.org/object/display.cfm?serv=1&id=3#3 3 Thu, 09 Jun 2011 23:00:00 GMT Do you need to know where value-based pricing (VBP) is going and how to master the practice of developing innovative pricing schemes? Value Based Pricing in Sweden: Is Swedish Experience Helpful in Designing Value Based Pricing in the UK? (Seminar) http://www.ohe.org/object/display.cfm?serv=1&id=6#6 6 Tue, 12 Apr 2011 23:00:00 GMT Ulf Persson,a member of the board of the Swedish pricing and reimbursement authority (TLV), a Professor in Health Economics at the University of Lund, and Chief Executive Officer at the Swedish Institute for Health Economics Risk-Sharing and Rebates: Is French Experience Helpful in Designing Value Based Pricing in the UK? (Seminar) http://www.ohe.org/object/display.cfm?serv=1&id=5#5 5 Fri, 11 Mar 2011 00:00:00 GMT Jacques Biot, a former senior government official and former senior industry executive, now an advisor to both the public and private sectors in the French drug licensing and reimbursement processes. Willingness to Pay and Publicly Funded Health Care: Contradiction in Terms? (Seminar) http://www.ohe.org/object/display.cfm?serv=1&id=4#4 4 Thu, 06 Jan 2011 00:00:00 GMT Prof. Cam Donaldson of Glasgow Caledonian University